Company Profile

FASgen Inc (AKA: Fasgen Diagnostics LLC~ FASgen LLC)
Profile last edited on: 6/4/19      CAGE: 334F9      UEI:

Business Identifier: Small molecule FAS inhibitors for cancer, obesity, and tuberculosis
Year Founded
1999
First Award
2002
Latest Award
2010
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

800 West Baltimore Street Suite 150
Baltimore, MD 21201
   (410) 558-9200
   N/A
   www.fasgen.com
Location: Single
Congr. District: 07
County: Baltimore City

Public Profile

With strong ties to Johns Hopkins and an exclusive license from that institution to more than 15 years of research in the field, FASgen, Inc. was formed as a drug development company by four distinguished researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. Under a sponsored research agreement with the University. FASgen set about designing and synthesizing many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds appeared to hold great promise for new highly specific therapeutics for cancer; additional compounds were judged to have the potential of specific therapeutics for obesity and related metabolic disorders; and, an additional group of compounds to have the potential of specific therapeutics for TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that affect one third of the world’s population. FASgen early developed small molecule compounds that the principals indicated were designed to limit the appetite and to boost the metabolic breakdown of excess fat stored in the body. Despite what had offered great promise, the firm appears to have discontinued operations

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
25-49

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 2 NIH $3,904,677
Project Title: Novel Small Molecule Therapeutics to Treat Obesity
2008 2 NIH $200,000
Project Title: Fatty Acid Synthase Phosphorylation as a Cancer Biomarker
2007 2 NIH $2,740,959
Project Title: Fatty Acid Synthase Inhibitors: Ovarian Cancer Therapy
2006 2 NIH $447,869
Project Title: Treatment of Latent TB and MDR-TB with FAS20013
2003 2 NIH $535,695
Project Title: Novel Compounds for Improved Treatment of Tuberculosis

Key People / Management

  Albert H Owens -- President and CEO

  Eric F Stoer -- CEO

  Francis P Kuhajda -- MD, CSO

  Susan Medghalchi

Company News